BIO-Europe 2026
Talk Presenting Companies (Theatre A) track
Immuno-Oncology: Pathios Therapeutics Limited
Mon, Nov 9, 2026 · 4:00–4:15 PM CET Koelnmesse
About this session
A clinical-stage oncology company focused on targeting GPR65 as a genetically-validated immunotherapy approach in cancer. We are pioneering the only approach to address the fundamental causal biology of the immunologically-hostile tumor microenvironment (TME)
